To the Copenhagen Stock Exchange
and the press

Announcement no. 24/2007

Interim report for the six months ended June 30, 2007

Summary: For the first six months of 2007 the Pharmexa Group generated revenues and other operating income of DKK 10,774 thousand and a net loss of DKK 92,954 thousand. Research and development costs totalled DKK 89,608 thousand. The Pharmexa Group expects a net loss for 2007 of DKK 190 million against previously expected DKK 185 million.

Status of the Group's activities

Pharmexa has a number of patented technology platforms within immunotherapy and vaccination which form the basis of a broad portfolio of drug candidates at all development stages, ranging from early research to Phase III clinical trials in patients. The company currently has eight product candidates that have reached the clinical trial stage. Pharmexa's project portfolio comprises cancer, chronic diseases, HIV and other serious infectious diseases. In addition to the current clinical trials, Pharmexa expects several of the company's preclinical projects to move into clinical development in 2008.

Commenting on the interim report, Pharmexa's CEO, Jakob Schmidt said: *"We continue to make advances in our projects. I am particularly pleased with the progress seen in our phase III trials of GV1001. If our osteoporosis vaccine PX107 shows the results we hope for in the next few months, we are looking at an extremely interesting clinical candidate next year. And our HIV projects are now starting to generate clinical results. The remainder of 2007 will be one of the most eventful in Pharmexa in recent years, with results anticipated from several clinical trials."*

Cancer	Chronic diseases	HIV	Infectious Diseases	
GV1001 (pancreatic cancer)				***Phase III***
GV1001 (liver cancer) GV1001 (lung cancer) PX104 (breast cancer)				***Phase II***
PX103 (breast cancer)		EP1090 EP1043 ***EP1232*** EP1233	EP2210 (hepatitis B)	***Phase I***
	PX107 (Osteoporosis) ***PX106 (Alzheimers)***		***EP2220 (hepatitis C)*** ***EP2230 (H. Papiloma Virus)*** EP1300 (malaria)	***Preclinical***
			EP1400 (influenza)	***Research***

Technology platforms

AutoVac™ PADRE® Peptide vaccines Polyepitope vaccines EIS®

Projects in *italics* have been licensed to third parties. Pharmexa has licence agreements with H. Lundbeck, Bavarian Nordic, Innogenetics and others. ImmunoVaccine Technologies have informed Pharmexa that they will not pursue further preclinical studies with a vaccine candidate containing the PADRE epitope.

Cancer

The PrimoVax trial, a pivotal Phase III trial of GV1001 in patients with pancreatic cancer, is progressing according to plans. More than 60 hospitals in a number of Western European countries and Australia are enrolling patients for this trial. Following approval from the FDA in May 2007, Pharmexa is now also enrolling patients from a number of US hospitals. Final results from the trial are expected in 2009 with a submission for registration in 2010.

The second Phase III study with GV1001, the TeloVac trial to include 1,110 patients, began enrolling patients in March 2007. The trial is well underway and is currently enrolling patients from more than 20 hospitals in the United Kingdom. Approximately 70 hospitals will participate when the trial is fully up and running.

Enrolment of patients for the Phase II trials with GV1001 in liver cancer and lung cancer is progressing in accordance with the plans. The Phase II trial called HeptoVax of GV1001 in liver cancer is almost fully enrolled and preliminary results will be announced before the end of the year.

Chronic diseases

Pharmexa has initiated the final toxicology and efficacy study in nonhuman primates with PX107, the RANKL AutoVac® vaccine targeting osteoporosis and other bone diseases. Preliminary results are expected before the end of 2007. Pharmexa has previously announced preclinical results suggesting that vaccination against the RANKL protein using the AutoVac® technology may be effective in the control of bone loss and inflammation. If the toxicology study yields positive results, Pharmexa will initiate a Phase I trial of PX107 in the first half of 2008.

Production of the Alzheimer's vaccine PX106 has commenced with a view to accelerating the preclinical development of the programme. Earlier in the collaboration with H. Lundbeck, Pharmexa has obtained proof of concept of the vaccine in preclinical trials and has shown that the vaccine has potential safety advantages over a competing vaccine candidate.

HIV

Pharmexa has four HIV vaccines in Phase I. The company expects data from several of these trials in the course of the coming 6-12 months. It is expected that data from the Phase I trial testing the vaccines EP1090 and EP1043 will be presented by the HIV Vaccine Trials Network (HVTN) in October/November this year. Data from the Phase I/II trial of EP1090 administered with needle free delivery will be available before the end of the year.

Bavarian Nordic recently announced that the first Phase I study of EP1232 (called *MVA-BN® HIV polytope* by Bavarian Nordic) in 36 healthy subjects is progressing as planned with the completion of enrolment and all vaccinations. According to Bavarian Nordic, all vaccinations were well tolerated and the first immunogenicity data from this novel vaccine concept are expected during the fourth quarter 2007.

The second Phase I study of this vaccine is in 30 HIV infected subjects and is also progressing on schedule according to Bavarian Nordic. Enrolment has been completed with the majority of subjects having already been vaccinated twice with the vaccine against HIV.

A third Phase I study that is sponsored by the NIH as part of a joint RFP between Bavarian Nordic and Pharmexa-Epimmune was initiated in the second quarter of 2007 by the HVTN. This study will evaluate the *MVA-BN® HIV polytope* vaccine in conjugation with a matched DNA vaccine (EP1233) in healthy subjects. Enrolment is on schedule.

Bavarian Nordic has furthermore announced that two Phase I/II clinical trials with Pharmexa's breast cancer vaccine PX103 delivered in Bavarian Nordic's MVA-BN® vector (called *MVA-*

BN®-HER2 by Bavarian Nordic) have been initiated in the U.S. and Europe and are proceeding according to schedule.

Other infectious diseases
EP1300, Pharmexa's late preclinical programme in malaria developed under a grant from the NIH is being prepared for Phase I testing in 2008.

Pharmexa has made good progress in the influenza programme. The company hopes to obtain proof of concept in animal models for two unique influenza vaccine approaches in the course of the coming 6 months.

Announcements to the Copenhagen Stock Exchange during the second quarter of 2007
Below is a summary of significant events during the period from March 31 to June 30, 2007:

- On May 21, Pharmexa announced that Ole Steen Andersen, Chairman of the Board of Directors in Pharmexa had acquired 15.000 shares.

- On May 29, Pharmexa announced that Professor Trond Buanes from Ullevål University Hospital would be presenting data on ASCO from a study of two RAS peptide vaccines in resectable pancreatic cancer, the marketing right of which belongs to Pharmexa.

- On June 4, Professor Trond Buanes presented data on ASCO: A follow-up study of 23 resected pancreatic cancer patients immunized in the period from 1995 to 1998 with two different peptide vaccines targeting the RAS mutation found in most instances of pancreatic cancer indicated that a long lasting immune response is possible following immunization with a peptide vaccine. Five patients that showed an immune response to the vaccine combination were still alive in 2006, i.e. up to 10 years after the operation. Further analysis showed that the immune system in three of these patients still remembered the RAS vaccination.

- On June 21, Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presented selected data from its influenza vaccine program at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The data indicated that an experimental vaccine under development by Pharmexa-Epimmune protected partially "humanized" transgenic mice against a lethal influenza virus infection.

Outlook for the Financial Year 2007
As a result of delayed operating income from NIH grants in the first half of 2007, the Group expects revenue and other operating income in the order of DKK 25 million against previously forecasted DKK 30 million. The Group's research and development costs are still expected to be in the order of DKK 185 million. The administrative expenses are expected to be in the order of DKK 30 million. For 2007, the Group therefore expects a net loss including financial income in the order of DKK 190 million against DKK 185 previously expected.

Directors' and Management's statement on the interim report
The Board of Directors and the Management have today considered and adopted the Interim Report for the period January 1 – June 30, 2007.

The interim report is prepared in accordance with IAS 34 and any additional Danish disclosure requirements for the presentation of financial statements by listed companies. The interim report is not audited.

We consider the accounting policies to be appropriate, the practised accounting estimates to be reasonable and the complete presentation of the interim report to meet the requirements, so that the interim report, in our opinion, gives a true and fair view of the assets, liabilities, financial position and results of operations and cash flows of the company for the period January 1 – June 30, 2007.

Hørsholm, August 23, 2007

Executive Management

Jakob Schmidt

Board of Directors

Ole Steen Andersen Chairman	Jørgen Buus Lassen	Karl Olof Borg
Alf A. Lindberg	Michel Pettigrew	Karen Lykke Sørensen
Finn Stausholm Nielsen	Tomas Wikborg	

Additional information*:*
Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525
Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558

Certain parts of this release contain forward-looking information with respect to the plans, projections and future performance of the company, each of which involves significant uncertainties. The company's actual results may differ materially from the information set forth in these statements.

This is an English translation of the interim report for the first 6 months of 2007 made in Danish. In case of any discrepancies between the Danish version and this English translation thereof, the Danish version shall prevail.

Summary financial figures (unaudited)

(DKK'000 except key figures)	Jan. 1 – June 30, 2007	Jan. 1 – June 30, 2006	Jan. 1 – Dec. 31, 2006
	Group	Group	Group
Condensed income statement			
Net revenues	56	1,662	2,040
Research costs	-24,386	-22,901	-47,644
Development costs	-65,222	-57,280	-117,443
Administrative expenses	-17,129	-17,598	-32,335
Loss before other operating income/expenses	-106,681	-96,117	-195,382
Other operating income	10,718	9,001	21,855
Other operating expenses	0	0	-70
Operating loss	-95,963	-87,116	-173,597
Profit/loss on net financials	3,009	1,912	4,547
Profit/loss before tax	-92,954	-85,204	-169,050
Net income/loss	**-92,954**	**-85,204**	**-169,050**
Depreciations and write-downs on non-current assets	6,955	9,411	13,786
Current EPS and diluted EPS (DKK 10 per share)	-1.2	-2.3	-4.5

Summary financial figures (continued)

(DKK'000 except key figures)	Jun. 31, 2007	Jun. 30, 2006	Dec. 31, 2006
	Group	Group	Group
Condensed balance sheet			
Intangible assets	81.411	122,787	86,734
Tangible fixed assets	12.788	17,736	15,451
Marketable securities	0	0	0
Cash and cash equivalents	142,887	249,805	165,260
Other current assets	15,646	16,344	17,446
Assets	**252,732**	**406,672**	**284,891**
Equity	226,028	376,399	258,219
Non-current liabilities	2,330	13,022	4,998
Current liabilities	24,374	17,251	21,674
Liabilities	**252,732**	**406,672**	**284,891**

(DKK'000 except key figures)	Jan. 1 – Jun. 30, 2007	Jan. 1 – Jun. 30, 2006	Jan. 1 – Dec. 31, 2006
	Group	Group	Group
Condensed cash flow statement			
Cash flow from operating activities before net financials	-82,105	-81,081	-162,458
From operating activities	-78,776	-78,092	-156,406
From investing activities	-633	68,584	66,924
hereof sale of marketable securities	0	70,853	70,853
hereof purchase of enterprises/investments in group enterprises	0	0	0
hereof invested in tangible fixed assets and intangible assets	-633	-2,269	-3,929
From financing activities	57,294	235	-3,723
Change in cash and cash equivalents	**-22,115**	**-9,273**	**-93,205**
Cash and cash equivalents at the beginning of period	165,260	260,324	260,324
Exchange rate adjustments	-258	-1,246	-1,859
Cash and cash equivalents at the end of period	**142,887**	**249,805**	**165,260**

Summary financial figures (continued)

(DKK'000 except key figures)	Jan. 1 – Jun. 30, 2007	Jan. 1 – Jun. 30, 2006	Jan. 1 – Dec. 31, 2006
	Group	Group	Group
Key figures			
Current EPS and diluted EPS (DKK 10 per share)	-1.2	-2,3	-4.5
Average number of shares	40,554,941	37,608,283	37,649,206
Number of shares, end of period	41,454,395	37,689,240	37,689,240
Net asset value (DKK 10 per share)	5,6	10,0	6.9
Share-price, end of period	18.1	21,4	17.5
Price/net asset value	3,23	2.14	2.56
Assets/equity	1.12	1.08	1.10
Number of employees (full-time equivalents), end of period	103	103	107
Number of employees (full-time equivalents), average	103	101	104

The ratios have been calculated in accordance with "Recommendations & Ratios 2005" issued by the Danish Society of Investment Professionals, dated December 2004

Development in share capital	**Jan. 1 – Jun. 30, 2007**	**2006**	**2005**	**2004**
	t.kr.	**t.kr.**	**t.kr.**	**t.kr.**
Share capital at the beginning of period	**376,893**	**375,999**	**163,999**	**40,999**
Capital increase	37,651	0	212,000	123,000
Warrant exercise	0	894	0	0
Share capital at the end of period	**414,544**	**376,893**	**375,999**	**163,999**

Summary financial figures (continued)

Development in shareholders' equity	Share capital	Share premium	Conditional share-holders' equity	Other equity	Total
	DKK'000	DKK'000	DKK'000	DKK'000	DKK'000
Equity as of January 1, 2007	376,893	0	0	-118,674	258,219
Capital increase	37,651	26,356	0	0	64,007
Costs of capital increase	0	0	0	-4,074	-4,074
Warrants	0	0	0	2,571	2,571
Loss for the period	0	0	0	-92,954	-92,954
Transfer to cover loss	0	-26,356	0	26,356	0
Exchange adjustments, foreign subsidiaries	0	0	0	-1,741	-1,741
Equity as of June 30, 2007	**414,544**	**0**	**0**	**-188,516**	**226,028**
Equity as of January 1, 2006	375,999	49,561	33,000	5,061	463,621
Costs of capital increase, previous year	0	-103	0	0	-103
Warrants	894	805	0	3,017	4,716
Loss for the period	0	-50,263	0	-34,941	-85,204
Exchange adjustments, foreign subsidiaries	0	0	0	-6,631	-6,631
Equity as of June 30, 2006	**376,893**	**0**	**33,000**	**-33,494**	**-376,399**

Warrant status

Movements in the number of warrants can be specified as:

	Staff[1)]	Management	Board of Directors	Others	Total
January 1, 2007	2,363,130	722,790	0	0	3,085,920
Change in status	0	0	0	0	0
Issued during the year	150,000	0	0	0	150,000
Issued as per June 30, 2007	**2,513,130**	**722,790**	**0**	**0**	**3,235,920**

Exercised and cancelled warrants can be specified as:

Issued as per June 30, 2007	2,513,130	722,790	0	0	3,235,920
Exercised during 2006	67,400	22,000	0	0	89,400
Cancelled during 2006	0	0	0	0	0
Expired during 2006	856,000	249,000	0	0	1,105,000
Issued outstanding warrants as per June 30, 2007	**1,589,730**	**451,790**	**0**	**0**	**2,041,520**

[1)] Including warrants issued to employee representative in the Board of Directors

Warrant status (continued)

As of June 30, 2007 outstanding warrants issued by the Company can be specified as the following:

	Exercise price	Outstanding warrants	Exercise Period	Market value per warrants*	Market value
	DKK per share	Number		DKK	DKK
Staff					
	27	149,730	7. Dec. 2007	0.44	65,881
	22.6	642,500	6. Jun. 2008	2,25	1,445,625
	27.1	47,500	6. Jun. 2008	1.34	63,650
	21	600,000	10. Jun. 2009	4,51	2,706,000
	17.5	150,000	26. Mar. 2010	6,76	1,014,000
		1,589,730			5,295,156
Management					
	27	46,790	7. Dec. 2007	0.44	20,588
	22.6	205,000	6. Jun. 2008	2,25	461,250
	21	200,000	10. Jun. 2009	4,51	902,000
		451,790			1,383,838
Total		**2,041,520**			**6,678,994**

*) The stated market value is calculated on basis of Black-Scholes formula for valuation of warrants. The calculations have been based on the same assumptions of no dividend, a volatility of 50%, a risk free interest rate of 4.59% pro anno, and finally the share price of Pharmexa on June 30, 2007 DKK 18,1 per share.

Comments on the interim report for the first 6 months of 2007

The report for the first 6 months of 2007 for the Pharmexa Group follows the same accounting policies as those set out in the Group's Annual Report 2006 and has been prepared in accordance with the International Financial Reporting Standards (IFRS) according to IAS 34 as well as the general requirements of the Copenhagen Stock Exchange to the financial reporting of listed companies.

Net revenues in the Pharmexa Group totalled DKK 56 thousand in the first 6 months of 2007 compared to DKK 1,662 thousand in the same period of 2006, representing a decrease of 97%. The decrease is mainly due to a reduced research funding provided under the collaborative agreements with H. Lundbeck and Innogenetics.

Research costs increased by 6% to DKK 24,386 thousand in the first 6 months of 2007 compared to DKK 22,901 thousand in the same period of 2006. Research costs are charged with DKK 355 thousand in respect of granted warrants originating from Pharmexa's warrant programme. When leaving the issuing of warrants out of the accounts the research costs increased by 9% to DKK 24,031 thousand in the first 6 months of 2007 compared to DKK 21,954 thousand in the same period of 2006.

Development costs increased by 14% to DKK 65,222 thousand in the first 6 months of 2007 compared with DKK 57,280 thousand in the same period in 2006. The increase is mainly due to the start-up of the Phase III trials with GV1001 and an increase in the pre-clinical costs for PX107 in preparation of a Phase I trial in 2008. In addition, the capitalised patent portfolios, projects, trademarks etc. from GemVax and IDM Pharma are amortised over their expected life.

Development costs are furthermore charged with DKK 1,057 thousand in respect of granted warrants originating from Pharmexa's warrant programme. When leaving the issuing of warrants out of the accounts the development costs increased by 14% to DKK 64,165 thousand in the first 6 months of 2007 compared to DKK 56,414 thousand in the same period of 2006.

Administrative expenses were reduced by 3% to DKK 17,129 thousand in the first 6 months of 2007 compared to DKK 17,598 thousand in the same period of 2006. When leaving the issuing of warrants out of the accounts the administrative expenses were reduced by 3% to DKK 15,971 thousand in the first 6 months of 2007 compared to DKK 16,394 thousand in the same period of 2006.

Other operating income amounted to DKK 10,718 thousand in the first 6 months of 2007 compared to DKK 9,001 thousand in the same period of 2006. Other operating income mainly consists of received grants from public authorities.

Net financial income amounted to DKK 3,009 thousand in the first 6 months of 2007 compared to DKK 1,912 thousand in the same period of 2006. Financial expenses of DKK 700 thousand consisted primarily of interest on a loan granted by VækstFonden, whereas Pharmexa realised interest income and capital gains of DKK 3,709 thousand primarily from cash and cash equivalents.

The net loss for the first 6 months of 2007 totalled DKK 92,954 thousand compared to DKK 85,204 thousand in the same period of 2006. The financial result is in accordance with expectations.

The value of expired Warrants DKK 4.909 has been posted directly on Equity according to IAS standard.

As of June 30, 2007 the Pharmexa Group's total assets amounted to DKK 252,732 thousand and cash and cash equivalents amounted to DKK 142,887 thousand.